Every honest conversation about testosterone replacement therapy has, for the last twenty years, included some version of the same question: "is this safe for my heart?" The answer, until 2023, was a hedged version of "probably, but the data is mixed." Two FDA black-box warnings, several flawed observational studies, and a generation of cautious primary-care medicine were all built on top of that uncertainty. The TRAVERSE trial — published in the New England Journal of Medicine in June 2023 and now extended through follow-up analyses into 2025 and 2026 — replaced "probably" with a defensible answer. It is the single most important reason a physician-led practice can today recommend hormone optimization to a symptomatic hypogonadal man without hedging.
What TRAVERSE actually tested.
TRAVERSE was a prospective, randomized, double-blind, placebo-controlled, non-inferiority trial of 5,246 men aged 45 to 80 with two morning testosterone measurements below 300 ng/dL, symptoms of hypogonadism, and either pre-existing cardiovascular disease or a high cardiovascular risk profile. Participants were randomized to topical testosterone gel (titrated to a 350–750 ng/dL range) or placebo. Mean treatment duration was 21.7 months; mean follow-up was 33 months. The primary composite endpoint was major adverse cardiovascular events — cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
The headline result: testosterone therapy was non-inferior to placebo for the primary cardiovascular endpoint. MACE occurred in 7.0% of the TRT arm and 7.3% of the placebo arm — a hazard ratio of 0.96 (95% CI 0.78 to 1.17). The pre-specified non-inferiority margin (a hazard ratio under 1.5) was crossed by a wide margin. There was no signal of harm.
The secondary endpoints.
The secondary safety endpoints were where the noise had been loudest in observational data, and TRAVERSE addressed each one directly:
Prostate cancer. Incidence was 0.5% on TRT versus 0.4% on placebo. No increase in high-grade disease. The men in TRAVERSE were monitored aggressively with PSA and digital rectal exams, and the trial detected no excess prostate cancer signal.
Venous thromboembolism. Incidence was 2.2% on TRT versus 1.5% on placebo. There was a small numerical increase, statistically not significant in the primary analysis but flagged in subsequent reviews. The clinical implication is that hematocrit and personal/family VTE history matter — both already part of the standard hormone-optimization workup.
Atrial fibrillation. Incidence was 3.5% on TRT versus 2.4% on placebo — a small, real, statistically detectable increase. This is the one signal worth taking seriously, and it informs how we monitor men with prior arrhythmia history or palpitations on therapy.
Acute kidney injury, fractures, sleep apnea. No meaningful between-group differences on the primary measures.
What it does not answer.
TRAVERSE was a trial of symptomatic men with biochemical hypogonadism — not a trial of "low-normal" men, men using testosterone for athletic performance, or men using injectable cypionate at higher target ranges. The dose used was a transdermal gel titrated into the mid-normal range. The men were not optimized into the upper end of the reference range, and they were not on adjunctive therapy like aromatase inhibitors. So the safety read is specifically for the population the trial enrolled. Extrapolating to men who are biochemically borderline, men who target higher levels, or men using non-gel formulations involves judgment beyond the trial data — judgment that should be made by a physician who knows the literature, not by an algorithm or a marketing funnel.
What it does change in clinic.
Three things, in order of importance.
One. The cardiovascular safety conversation is now anchored to a randomized trial of more than five thousand men, not to extrapolation from observational cohorts of variable quality. The conversation gets shorter and the patient leaves more confident in the recommendation.
Two. The atrial fibrillation signal is real and worth screening for. Baseline ECG, history of palpitations, and family history of arrhythmia are now part of the pre-treatment intake at Limitless — not because every patient gets one, but because the right patient gets one.
Three. Hematocrit monitoring, already standard, has additional justification. We pull a CBC at baseline, three months, six months, and annually. Hematocrit above 54% triggers a dose reduction or therapeutic phlebotomy — the same standard that has always applied, now with a TRAVERSE-grade rationale.
How this shapes the Limitless framework.
Our clinical philosophy on hormone optimization has always been functional ranges over standard reference ranges, evidence-informed dosing, and aggressive but disclosed risk management. TRAVERSE is the trial that makes the first half of that statement defensible to any cardiologist or internist who asks. The conservative half — careful screening, baseline labs that go beyond what most primary-care practices run, structured monitoring at three and six months and annually thereafter — is also reinforced by the trial. A real read of TRAVERSE does not make us more aggressive. It makes us more confident in the framework we already use, and clearer in how we explain it. The full Limitless approach to testosterone optimization lives at /hrt-dalton-ga and the broader protocol context at /limitless-protocol.
If you have been told testosterone therapy is dangerous to your heart, the data no longer supports that statement for symptomatic hypogonadal men. If you have been told it is risk-free, the data does not support that either. The right answer — small, real, manageable risks; meaningful symptomatic benefit; physician-led monitoring — is the answer the trial supports, and it is the answer we operate on.
The 2026 update — what we still watch.
"Reassuring" is not "risk-free," and we keep the moving parts in view. Three developments since the primary readout sharpen the picture, and we tell patients all three. First, in 2025 the FDA removed the boxed cardiovascular warning from testosterone labeling — but added a blood-pressure warning, because testosterone can raise BP; products remain approved only for confirmed hypogonadism, not ordinary aging. Second, a 2026 Mendelian-randomization analysis found that men with genetically higher lifelong testosterone carried roughly a 17% higher risk of coronary artery disease, likely mediated in part through blood pressure. That is a different question from "is prescribed TRT safe in hypogonadal men" — TRAVERSE answers that yes — but it is a reason for humility rather than salesmanship, and it puts blood-pressure management squarely inside the protocol alongside the hematocrit and AFib monitoring we already run.
Third — and this is the distinction that matters most in clinic — lifelong genetic exposure is not the same as therapeutic restoration. The Mendelian-randomization signal describes men whose bodies ran high testosterone for fifty years; TRT in a hypogonadal man restores a deficient level into the physiologic range for a defined therapeutic reason. The 2026 position statement of the European Expert Panel for Testosterone Research (Zitzmann et al., Andrology), which synthesized TRAVERSE with the broader evidence base, lands in the same place we do: testosterone therapy in properly diagnosed hypogonadal men is cardiovascularly acceptable and carries a meaningful additional benefit — it corrects the anemia of hypogonadism by restoring normal red-cell production — provided hematocrit and blood pressure are monitored. Restoring a physiologic level under monitoring is the indication. Chasing a supraphysiologic number is not, and we do not do it.
We optimize with confidence — and we show you the risk signals.
None of this stops us from treating hypogonadal men — it shapes how. We confirm a real biochemical and symptomatic diagnosis before starting; we monitor blood pressure and hematocrit on a schedule, not by feel; we flag AFib and clotting history before the first dose; and we titrate to a physiologic, symptom-resolving level rather than the highest number a patient asks for. The clinic down the road sells testosterone as risk-free vitality. We hand you the same trial data we read — the reassurance and the asterisks — because a patient who can see the risk signals is a patient who can actually consent. That is what physician-led is supposed to mean.